Cambridge Nutritional Sciences PLC (LSE:CNSL) is about as far from the market's radar as a listed company can get. The food-sensitivity testing specialist, formerly Omega Diagnostics, is valued at roughly £4.4m, trades at under 2p a share and has slid from a 52-week high of 3.25p last September to a low of 1.70p in June 2026, according to lse.co.uk data.

That obscurity is precisely why some investors hunt in this corner of the London Stock Exchange. The immediate question is whether the Ely-based group can turn improving gross margins and growth in the UK and India into a return to profitability, at a moment when its audited results for the year to 31 March 2026 have been delayed twice and are now due on 8 September 2026.

Results delayed again as Revenue slips to £7.0m

On 17 August 2026 Cambridge Nutritional Sciences pushed back publication of its audited annual results for the second time. The company had guided in April that results would appear in July, then set 18 August in a notice on 3 August, before moving the date to Tuesday 8 September. The board blamed "auditor and Company bandwidth in the audit process", while stressing that "revenue, EBITDA and cash remain in line with market expectations as reported".

Those expectations were set in a trading and Business update on 22 April 2026. Unaudited revenue for the year ended 31 March 2026 fell to £7.0m from £8.3m, a drop of about 16%, which management blamed on reduced and delayed orders from the Middle East and Asia amid geopolitical instability rather than lost customer relationships. Excluding those regions, underlying revenue grew by around 11%, led by the UK and India.

The gross Margin rose to 67.8% from 65.3%, but the lower sales base tipped adjusted EBITDA to a £0.4m loss against a £0.4m profit a year earlier. Net cash fell to £2.6m from £4.9m, partly reflecting Capital Investment in equipment for the group's In Vitro Diagnostic Regulation (IVDR) programme.

Chief executive James Cooper said he was "pleased that underlying revenue adjusting for economic disruption showed 11% growth", crediting "manufacturing efficiencies" for the margin gain and arguing that the IVDR work would "deliver significant product, cost and market position advantages" over the long term, while flagging caution on continuing global uncertainty.

What Cambridge Nutritional Sciences does

The group develops, manufactures and distributes medical diagnostics for the food sensitivity market through its operating Subsidiary Omega Diagnostics Ltd, based at Littleport, near Ely. Its CE-marked tests detect IgG antibodies to foods using immunoassay technology, drawing on more than 35 years of in-house development.

The flagship FoodPrint® range is a laboratory panel covering up to 207 foods, sold direct to consumers through the CNSLab service with an at-home finger-prick kit, and through a network the company says exceeds 3,000 UK clinicians. Food Detective® is a professional-use point-of-care test sold mainly through international distributors. In August 2025 the group launched Gut Detective®, a CE-marked stool biomarker panel for UK practitioners.

In the year to 31 March 2025, FoodPrint® generated £4.84m of revenue, Food Detective® £1.79m and the CNSLab service £1.63m. Sales are spread widely: the UK contributed £1.65m, the rest of Europe £1.99m, the Americas £1.48m, Asia £1.91m, India £0.69m and Africa and the Middle East £0.61m, which explains why regional disruption hit the FY26 Top Line so hard.

Financial performance: a profitable FY25 flattered by a one-off, a loss-making FY26

The last audited numbers cover the year to 31 March 2025. Revenue fell 14.8% to £8.3m from £9.8m, the gross margin improved by 340 basis points to 65.3% and adjusted EBITDA rose to £0.4m from £0.2m. Reported profit before tax was £1.6m, against a £0.7m loss in FY24, with Basic Earnings Per Share of 0.7p. That headline profit was driven by £1.8m of net exceptional income, chiefly a £2.5m settlement from the Department of Health and Social Care, offset by legal costs and a £35,000 Health and Safety Executive fine relating to a division sold in 2018. Cash and deposits ended FY25 at £4.9m. No Dividend was paid.

The first half of FY26, reported on 10 November 2025, showed revenue down 6.6% to £3.9m, adjusted EBITDA of £0.1m and a pre-tax loss of £0.4m, with cash of £3.6m at 30 September 2025. UK sales grew 6% and India 33%, while mainland Europe fell 26%. The FY25 going-concern assessment noted that revenue could fall a further 45% before cash was exhausted; investors will want an updated version of that analysis in the FY26 accounts, given cash has since fallen to £2.6m.

What could move the shares next

The obvious near-term event is 8 September 2026, when the audited FY26 results and an Investor Meet Company presentation from Mr Cooper and chief financial officer Ajay Patel are scheduled. Commentary on Middle East and Asian order flow would show whether the FY26 shortfall was a timing issue or something more structural.

Beyond that, the growth case rests on the UK practitioner and direct-to-consumer channel, which grew in both FY25 and H1 FY26; India, the fastest-growing region; and international laboratory partnerships that management said in August 2025 should deliver their main benefits within two years. The IVDR programme, targeting compliance by end-2029, the Gut Detective® launch and a restructured sales team are the operational levers to watch.

Risks investors should watch

Cash is the central issue. Net cash fell by £2.3m over FY26 to £2.6m while adjusted EBITDA turned negative, and the company continues to invest in IVDR equipment and a new laboratory information system. If revenue does not recover, the group could need to cut costs further or raise equity, which at a Market Value of about £4.4m would be highly dilutive.

The twice-delayed audit is a governance flag in its own right, even if the board says the numbers are unchanged. Exposure to politically unstable export markets has already knocked around 16% off annual revenue. The clinical validity of IgG-based food sensitivity testing is contested by parts of the medical community, which could affect practitioner adoption or regulation. Liquidity is thin: with a bid-ask spread of 1.70p to 2.00p, exiting a position can itself move the price.

Outlook

Cambridge Nutritional Sciences enters the FY26 results with improving margins, growth in its home market and in India, and a modest but shrinking cash cushion. The 8 September announcement should clarify whether the audit delay was purely administrative, how the board views Middle East and Asian orders, and how long the current cash balance is expected to last. Investors weighing the "sleeper" thesis will need evidence that underlying growth can outrun the cash burn. Until then, this remains a speculative micro-cap whose next move depends heavily on a single results day.